| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S12727 R48014 |
Bjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
1.13 [0.91;1.40] excluded (control group) |
82/7,950 38,437/4,463,879 | 38,519 | 7,950 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12728 R48015 |
Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.83 [0.65;1.07] C | 82/7,950 267/21,634 | 349 | 7,950 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8978 R39746 |
Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.30 [0.70;2.40] | 10/2,813 4,254/1,707,707 | 4,264 | 2,813 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8956 R39728 |
Wiggs (Lamotrigine), 2020 | Austism Spectrum Disorder (after 2 years of age) | at least 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 0.66 [0.27;1.58] | -/- -/11,298 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9931 R39727 |
Bjørk (Lamotrigine) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
2.05 [1.13;3.72] C excluded (control group) |
13/76 6,907/75,497 | 6,920 | 76 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9973 R39726 |
Bjørk (Lamotrigine) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.87 [0.91;3.84] C | 13/76 27/272 | 40 | 76 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8941 R39754 |
Cohen-Israel (Lamotrigine), 2018 | Autism (a majority between 6-12 years old) | 1st trimester | retrospective cohort | unexposed, disease free | Adjustment: No Matched | 0.33 [0.01;8.20] C | 0/83 1/83 | 1 | 83 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8933 R39739 |
Bromley (Lamotrigine) (Controls unexposed, disease free), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.81 [0.20;16.76] C excluded (control group) |
1/30 4/214 | 5 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8936 R39743 |
Bromley (Lamotrigine) (Controls unexposed, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.68 [0.10;68.88] C | 1/30 0/26 | 1 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.02 [0.72;1.45] | 4,655 | 10,952 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Lamotrigine) (Controls unexposed, sick) (Mixed indications; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications; 3: Lamotrigine; 4: Lamotrigine) (Controls unexposed, sick; 5: Lamotrigine; 6: Lamotrigine) (Controls unexposed, sick;
Asymetry test p-value = 0.5379 (by Egger's regression)
slope=-0.1772 (0.2081); intercept=0.5281 (0.7848); t=0.6729; p=0.5379
excluded 8933, 9931, 12727